Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment
Public ClinicalTrials.gov record NCT03132675. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Keynote 695 is Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab or nivolumab.
Study identification
- NCT ID
- NCT03132675
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 143 participants
Conditions and interventions
Conditions
Interventions
- tavokinogene telseplasmid Biological
- Pembrolizumab Biological
- ImmunoPulse Device
Biological · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2017 (Actual)
- Primary completion
- Mar 31, 2023 (Estimated)
- Completion
- Jul 31, 2024 (Estimated)
- Last update posted
- Mar 27, 2023
2017 – 2024
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Yuma Regional Medical Center, Yuma Cancer Center | Yuma | Arizona | 85364 | — |
| University of California, San Diego | La Jolla | California | 92093 | — |
| UCSF Medical Center | San Francisco | California | 94115 | — |
| University of Colorado Anschutz Medical Campus University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| University of Miami Sylvester Cancer Center | Miami | Florida | 33136 | — |
| UF Health Cancer Center at Orlando Health | Orlando | Florida | 32806 | — |
| Moffit Cancer Center | Tampa | Florida | 33612 | — |
| Ochsner Cancer Institute | New Orleans | Louisiana | 70121 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan, Michigan Medicine Melanoma Oncology Clinic - Rogel Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Dartmouth Hitchcock Clinic | Lebanon | New Hampshire | 03756 | — |
| Atlantic Health System | Morristown | New Jersey | 07860 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Health Quest Systems, Inc. | Poughkeepsie | New York | 12601 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Penn State Health Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Texas Oncology/Baylor | Dallas | Texas | 75246 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03132675, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03132675 live on ClinicalTrials.gov.